Aurinia Pharmaceuticals AUPH Allowance for credit losses
Allowance for credit losses at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's allowance for credit losses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's allowance for credit losses?
- Aurinia Pharmaceuticals (AUPH) reported allowance for credit losses of $378.95M in Q1 2026.
- How has Aurinia Pharmaceuticals's allowance for credit losses changed year-over-year?
- Aurinia Pharmaceuticals's allowance for credit losses increased by 21.1% year-over-year, from $312.92M to $378.95M.
- What is the long-term trend for Aurinia Pharmaceuticals's allowance for credit losses?
- Over 2 years (2023 to 2025), Aurinia Pharmaceuticals's allowance for credit losses has grown at a 6.5% compound annual growth rate (CAGR), from $350.42M to $397.79M.
- What does allowance for credit losses mean?
- Reserve held against the loan portfolio for estimated future credit losses under the CECL methodology — a contra-asset reducing net loans.